

# Alexander Molokoedov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6479408/publications.pdf>

Version: 2024-02-01

24  
papers

316  
citations

840776

11  
h-index

888059

17  
g-index

33  
all docs

33  
docs citations

33  
times ranked

288  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric Agonist of Galanin Receptor GALR2 Reduces Heart Damage in Rats with Streptozotocin-Induced Diabetes. <i>Biochemistry (Moscow)</i> , 2022, 87, 346-355.	1.5	2
2	Exogenous Galanin Reduces Hyperglycemia and Myocardial Metabolic Disorders Induced by Streptozotocin in Rats. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, .	1.9	1
3	Antioxidant Properties of Galanin and Its N-Terminal Fragments in in vitro and in vivo Oxidative Stress Modeling. <i>Biochemistry (Moscow)</i> , 2021, 86, 496-505.	1.5	11
4	Galanin Peptides Alleviate Myocardial Ischemia/Reperfusion Injury by Reducing Reactive Oxygen Species Formation. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2039-2048.	1.9	4
5	[MeArg1, NLe10]-apelin-12: Optimization of solid-phase synthesis and evaluation of biological properties in vitro and in vivo. <i>Peptides</i> , 2020, 129, 170320.	2.4	6
6	Galanin and its N-terminal fragments reduce acute myocardial infarction in rats. <i>Peptides</i> , 2019, 111, 127-131.	2.4	13
7	Galanin receptors activation modulates myocardial metabolic and antioxidant responses to ischaemia/reperfusion stress. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 1174-1182.	1.9	8
8	Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia/reperfusion injury. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 1556-1562.	5.6	23
9	Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats. <i>Cardiovascular Toxicology</i> , 2019, 19, 136-146.	2.7	14
10	Solid-phase fragment condensation for synthesis of peptides from the immunodominant sequence of $\beta$ <sup>21</sup> -adrenoreceptor. <i>Russian Journal of Bioorganic Chemistry</i> , 2017, 43, 351-358.	1.0	1
11	Myocardial protection from ischemia/reperfusion injury by exogenous galanin fragment. <i>Oncotarget</i> , 2017, 8, 21241-21252.	1.8	38
12	Cardioprotective properties of N-terminal galanin fragment (2-15) in experimental ischemia/reperfusion injury. <i>Oncotarget</i> , 2017, 8, 101659-101671.	1.8	28
13	Design of peptidase-resistant peptide inhibitors of myosin light chain kinase. <i>Journal of Peptide Science</i> , 2016, 22, 673-681.	1.4	5
14	Synthetic conformational antigen which simulates the extracellular part of the M2-muscarinic receptor: interaction with blood sera of patients suffering from idiopathic arrhythmias. <i>Russian Journal of Bioorganic Chemistry</i> , 2013, 39, 252-258.	1.0	0
15	Effects of structural analogues of apelin-12 in acute myocardial infarction in rats. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 198.	0.4	28
16	Suppression of vascular endothelium hyperpermeability by cell-permeating peptide inhibitors of myosin light chain kinase. <i>Biophysics (Russian Federation)</i> , 2012, 57, 587-591.	0.7	1
17	Limitation of myocardial infarction by a structural analog of the peptide apelin-12. <i>Doklady Biological Sciences</i> , 2012, 443, 65-67.	0.6	7
18	The synthesis of immunomodulating peptide alloferon, the active principle of antiviral drug allokine-alpha. <i>Russian Journal of Bioorganic Chemistry</i> , 2006, 32, 136-145.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Peptide fragment 66–77 of monocyte chemoattractant protein 1 and its retro-enantio analogue inhibit the migration of cells in vitro and in vivo. Russian Journal of Bioorganic Chemistry, 2006, 32, 146-153.	1.0	1
20	Inhibition of migration of monocytes and granulocytes in vivo by the peptide corresponding to sequence 65–76 of monocyte chemotactic protein-1 (MCP-1). Doklady Biochemistry and Biophysics, 2006, 411, 339-341.	0.9	3
21	The Peptide of Sequence 66–77 of Monocytic Chemotactic Protein (MCP-1) Inhibits Inflammation in Experimental Animals. Doklady Biological Sciences, 2005, 404, 402-405.	0.6	6
22	Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as T-cadherin. FEBS Letters, 1998, 421, 208-212.	2.8	43
23	Phenotypic correction of the immune response with l-tyrosine in mice opposite in their response to sheep's red blood cells. Bulletin of Experimental Biology and Medicine, 1988, 106, 1595-1597.	0.8	0
24	Atriopeptin 2 is hydrolysed by cardiac but not pulmonary isozyme of angiotensin-converting enzyme. Biochemical and Biophysical Research Communications, 1988, 151, 109-113.	2.1	13